Apixaban Dosing for Pulmonary Embolism Treatment

Initial Treatment Phase

The European Society of Cardiology recommends apixaban 10 mg twice daily for 7 days for patients with pulmonary embolism, followed by 5 mg twice daily for at least 3 months 1
No initial parenteral anticoagulation is required before starting apixaban, unlike some other direct oral anticoagulants 2
Treatment can be initiated immediately upon diagnosis of pulmonary embolism, provided there are no contraindications 1

After the initial 7 days, the American College of Chest Physicians recommends reducing the dose to 5 mg twice daily 1
The American College of Chest Physicians suggests continuing treatment for at least 3 months 3
For patients with unprovoked pulmonary embolism or ongoing risk factors, extended anticoagulation may be necessary, as recommended by the European Society of Cardiology 1

The European Heart Journal recommends using apixaban with caution in severe renal impairment (creatinine clearance <30 mL/min) 4

The European Heart Journal reports that apixaban has been shown to have a lower rate of major bleeding (0.6%) compared to conventional therapy (1.8%) 1
The European Heart Journal also reports that the composite of major bleeding and clinically relevant non-major bleeding is significantly lower with apixaban (4.3%) compared to conventional therapy (9.7%) 1

The European Heart Journal advises against administering loading doses of parenteral anticoagulants when initiating apixaban, as this increases bleeding risk 2
The European Heart Journal recommends not continuing the initial higher dose beyond 7 days 1

The American College of Cardiology recommends a higher initial dose of apixaban, 10mg twice daily for the first 7 days, to ensure rapid therapeutic anticoagulation for the acute phase of pulmonary embolism treatment 5
Apixaban dosing for pulmonary embolism is standardized and not INR-dependent like warfarin, with a maintenance dose of 5mg twice daily after the initial 7-day period 5
The American Society of Hematology guidelines suggest that after 6 months of initial therapy, either 5mg twice daily or 2.5mg twice daily can be considered for extended secondary prevention, with the 2.5mg twice daily reduced dose of apixaban not being equivalent to warfarin 2.5mg 6

Dose adjustment may be necessary for patients with specific characteristics such as age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, and apixaban should be used with caution in patients with severe renal impairment 7
Unlike warfarin, apixaban does not require routine coagulation monitoring, as it has a more predictable anticoagulant effect 8, 9